Table 2.
Summary of determined vIC50 and vEC50 of antiviral drugs against SARS-CoV-2.
| Antiviral drugs | vIC50/vEC50 (μM) | vIC50/vEC50 used for EDRP calculation |
|
|---|---|---|---|
| μM | Converted to μg/L | ||
| Chloroquine | 1.03 (Holwerda et al., 2020) 1.13 (Wang et al., 2020a) 1.31 (Ohashi et al., 2020) 5.47 (Yao et al., 2020) 2.71–7.36 (Liu et al., 2020b) 7.28, 12.0 (Jeon et al., 2020) 9.27 (Xiong et al., 2020) |
1.03 | 329 |
| Favipiravir | 62 (Wang et al., 2020a) >500 (Jeon et al., 2020) |
62 | 9740 |
| Hydroxychloroquine | 0.72 (Yao et al., 2020) 4.51–12.96 (Liu et al., 2020b) 9.21–11.17 (Weston et al., 2020) |
0.72 | 242 |
| Lopinavir | 1.73 (Ohashi et al., 2020) 4.9–5.2 (Gonçalves et al., 2020) 5.73 (Yamamoto et al., 2020) 9.12, 15.27 (Jeon et al., 2020) |
1.73 | 1088 |
| Oseltamivir | >100 (Tan and Jin, 2020) >100 (Wang et al., 2020b) |
100 | 31,200 |
| Remdesivir | 0.77 (Wang et al., 2020a) 1.842 (Holwerda et al., 2020) 2.5 (Liu et al., 2020c) 8.24, 11.41 (Jeon et al., 2020) |
0.77 | 464 |
| Ribavirin | 109.5 (Wang et al., 2020a) | 109.5 | 26,740 |
| Ritonavir | 8.63 (Yamamoto et al., 2020) | 8.63 | 6222 |
| Teicoplanin | 1.66 (Zhang et al., 2020) | 1.66 | 3120 |
| Umifenovir | 4.11 (Wang et al., 2020b) 30 (Lu, 2020) |
4.11 | 1962 |